Clinical Trial Update: Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update of a pooled mutant KRAS-targeted long peptide vaccine combined with nivolumab and ipilimumab in patients with resected MMR-p colorectal and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Pancreatic Cancer

Drugs mentioned

• Pooled mutant KRAS-targeted long peptide vaccine (KRAS-targeted long peptide vaccine)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Colorectal Cancer, Pancreatic Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING